An inexpensive drug Antabuse as anticancer remedy: mechanism of action and clinical trials

Provider

Ministry of Education, Youth and Sports

Programme

—

Call for proposals

—

Main participants

—

Contest type

—

Contract ID

34522/13

Project name in Czech

Levný lék antabus jako protinádorové léčivo: mechanismus účinku a klinické testy

Annotation in Czech

Cíle:Začlenit cílovou skupinu do spolupráce s US vědeckými týmy na Harvard Medical School, GlobalCures a Barbara Ann Karmanos Cancer Institute na vývoji nového, levného léku proti rakovině v rámci koncepce tzv.non-profit drugs.

R&D category

AP - Applied research

CEP classification - main branch

FR - Pharmacology and apothecary chemistry

CEP - secondary branch

—

CEP - another secondary branch

—

OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

30104 - Pharmacology and pharmacy

Provider evaluation

U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

Project results evaluation

Project was implemented in accordance with the grant decision. The activity and the purpose of the project was completely filled. All outputs have been created and properly supported by the provider. The project has contributed to the emergence and improvement of the research and development teams with an emphasis on multidisciplinaritu and cooperation with the private sector.

Realization period - beginning

Sep 1, 2011

Realization period - end

Aug 31, 2014

Project status

U - Finished project

Latest support payment

Aug 21, 2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data delivery code

CEP15-MSM-EE-U/01:1

Data delivery date

Jul 2, 2015

Total approved costs

15,040 thou. CZK

Public financial support

15,040 thou. CZK

Other public sources

0 thou. CZK

Non public and foreign sources

0 thou. CZK